Brian Lehmann
Last active: 9/15/2015

Profile

None provided

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Detection of internal exon deletion with exon Del. Guo Y, Zhao S, Lehmann BD, Sheng Q, Shaver TM, Stricker TP, Pietenpol JA, Shyr Y (2014) BMC Bioinformatics : 332
    › Primary publication · 25322818 (PubMed) · PMC4288651 (PubMed Central)
  2. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Lehmann BD, Bauer JA, Schafer JM, Pendleton CS, Tang L, Johnson KC, Chen X, Balko JM, Gómez H, Arteaga CL, Mills GB, Sanders ME, Pietenpol JA (2014) Breast Cancer Res 16(4): 406
    › Primary publication · 25103565 (PubMed) · PMC4187324 (PubMed Central)
  3. Subtyping of triple-negative breast cancer: implications for therapy. Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol JA (2015) Cancer 121(1): 8-16
    › Primary publication · 25043972 (PubMed) · PMC4270831 (PubMed Central)
  4. Transforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer. Jovanović B, Beeler JS, Pickup MW, Chytil A, Gorska AE, Ashby WJ, Lehmann BD, Zijlstra A, Pietenpol JA, Moses HL (2014) Breast Cancer Res 16(4): R69
    › Primary publication · 24985072 (PubMed) · PMC4095685 (PubMed Central)
  5. Multi-perspective quality control of Illumina exome sequencing data using QC3. Guo Y, Zhao S, Sheng Q, Ye F, Li J, Lehmann B, Pietenpol J, Samuels DC, Shyr Y (2014) Genomics 103(5-6): 323-8
    › Primary publication · 24703969 (PubMed) · PMC5755963 (PubMed Central)
  6. Mislocalization of the cell polarity protein scribble promotes mammary tumorigenesis and is associated with basal breast cancer. Feigin ME, Akshinthala SD, Araki K, Rosenberg AZ, Muthuswamy LB, Martin B, Lehmann BD, Berman HK, Pietenpol JA, Cardiff RD, Muthuswamy SK (2014) Cancer Res 74(11): 3180-94
    › Primary publication · 24662921 (PubMed) · PMC4096808 (PubMed Central)
  7. New strategies for triple-negative breast cancer--deciphering the heterogeneity. Mayer IA, Abramson VG, Lehmann BD, Pietenpol JA (2014) Clin Cancer Res 20(4): 782-90
    › Primary publication · 24536073 (PubMed) · PMC3962777 (PubMed Central)
  8. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sánchez V, Kurupi R, Moore PD, Pinto JA, Doimi FD, Gómez H, Horiuchi D, Goga A, Lehmann BD, Bauer JA, Pietenpol JA, Ross JS, Palmer GA, Yelensky R, Cronin M, Miller VA, Stephens PJ, Arteaga CL (2014) Cancer Discov 4(2): 232-45
    › Primary publication · 24356096 (PubMed) · PMC3946308 (PubMed Central)
  9. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. Hutchinson KE, Lipson D, Stephens PJ, Otto G, Lehmann BD, Lyle PL, Vnencak-Jones CL, Ross JS, Pietenpol JA, Sosman JA, Puzanov I, Miller VA, Pao W (2013) Clin Cancer Res 19(24): 6696-702
    › Primary publication · 24345920 (PubMed) · PMC3880773 (PubMed Central)
  10. Comparative study of exome copy number variation estimation tools using array comparative genomic hybridization as control. Guo Y, Sheng Q, Samuels DC, Lehmann B, Bauer JA, Pietenpol J, Shyr Y (2013) Biomed Res Int : 915636
    › Primary publication · 24303503 (PubMed) · PMC3835197 (PubMed Central)
  11. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. Lehmann BD, Pietenpol JA (2014) J Pathol 232(2): 142-50
    › Primary publication · 24114677 (PubMed) · PMC4090031 (PubMed Central)
  12. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN, Symmans WF, Ueno NT (2013) Clin Cancer Res 19(19): 5533-40
    › Primary publication · 23948975 (PubMed) · PMC3813597 (PubMed Central)
  13. A data similarity-based strategy for meta-analysis of transcriptional profiles in cancer. Qiu Q, Lu P, Xiang Y, Shyr Y, Chen X, Lehmann BD, Viox DJ, George AL, Yi Y (2013) PLoS One 8(1): e54979
    › Primary publication · 23383020 (PubMed) · PMC3558433 (PubMed Central)
  14. Patient-derived breast tumor xenografts facilitating personalized cancer therapy. Landis MD, Lehmann BD, Pietenpol JA, Chang JC (2013) Breast Cancer Res 15(1): 201
    › Primary publication · 23339383 (PubMed) · PMC3672825 (PubMed Central)
  15. p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3. Chappell WH, Lehmann BD, Terrian DM, Abrams SL, Steelman LS, McCubrey JA (2012) Cell Cycle 11(24): 4579-88
    › Primary publication · 23187804 (PubMed) · PMC3562303 (PubMed Central)
  16. Targeting mutant p53 in human tumors. Lehmann BD, Pietenpol JA (2012) J Clin Oncol 30(29): 3648-50
    › Primary publication · 22965952 (PubMed)
  17. TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer. Chen X, Li J, Gray WH, Lehmann BD, Bauer JA, Shyr Y, Pietenpol JA (2012) Cancer Inform : 147-56
    › Primary publication · 22872785 (PubMed) · PMC3412597 (PubMed Central)
  18. Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells. Taylor JR, Lehmann BD, Chappell WH, Abrams SL, Steelman LS, McCubrey JA (2011) Oncotarget 2(8): 610-26
    › Primary publication · 21881167 (PubMed) · PMC3248208 (PubMed Central)
  19. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA (2011) J Clin Invest 121(7): 2750-67
    › Primary publication · 21633166 (PubMed) · PMC3127435 (PubMed Central)
  20. RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells. Bauer JA, Ye F, Marshall CB, Lehmann BD, Pendleton CS, Shyr Y, Arteaga CL, Pietenpol JA (2010) Breast Cancer Res 12(3): R41
    › Primary publication · 20576088 (PubMed) · PMC2917036 (PubMed Central)
  21. Attenuation of myocardial injury in mice with functional deletion of the circadian rhythm gene mPer2. Virag JA, Dries JL, Easton PR, Friesland AM, DeAntonio JH, Chintalgattu V, Cozzi E, Lehmann BD, Ding JM, Lust RM (2010) Am J Physiol Heart Circ Physiol 298(3): H1088-95
    › Primary publication · 20061537 (PubMed) · PMC2838551 (PubMed Central)
  22. Senescence-associated exosome release from human prostate cancer cells. Lehmann BD, Paine MS, Brooks AM, McCubrey JA, Renegar RH, Wang R, Terrian DM (2008) Cancer Res 68(19): 7864-71
    › Primary publication · 18829542 (PubMed) · PMC3845029 (PubMed Central)
  23. Targeting prostate cancer based on signal transduction and cell cycle pathways. Lee JT, Lehmann BD, Terrian DM, Chappell WH, Stivala F, Libra M, Martelli AM, Steelman LS, McCubrey JA (2008) Cell Cycle 7(12): 1745-62
    › Primary publication · 18594202 (PubMed) · PMC2593475 (PubMed Central)
  24. Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy. McCubrey JA, Sokolosky ML, Lehmann BD, Taylor JR, Navolanic PM, Chappell WH, Abrams SL, Stadelman KM, Wong EW, Misaghian N, Horn S, Bäsecke J, Libra M, Stivala F, Ligresti G, Tafuri A, Milella M, Zarzycki M, Dzugaj A, Chiarini F, Evangelisti C, Martelli AM, Terrian DM, Franklin RA, Steelman LS (2008) Adv Enzyme Regul : 113-35
    › Primary publication · 18423407 (PubMed) · PMC2583357 (PubMed Central)
  25. Distinct roles for p107 and p130 in Rb-independent cellular senescence. Lehmann BD, Brooks AM, Paine MS, Chappell WH, McCubrey JA, Terrian DM (2008) Cell Cycle 7(9): 1262-8
    › Primary publication · 18418057 (PubMed) · PMC3474322 (PubMed Central)
  26. Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. Steelman LS, Navolanic PM, Sokolosky ML, Taylor JR, Lehmann BD, Chappell WH, Abrams SL, Wong EW, Stadelman KM, Terrian DM, Leslie NR, Martelli AM, Stivala F, Libra M, Franklin RA, McCubrey JA (2008) Oncogene 27(29): 4086-95
    › Primary publication · 18332865 (PubMed) · PMC3836277 (PubMed Central)
  27. Radiosensitization of prostate cancer by priming the wild-type p53-dependent cellular senescence pathway. Lehmann BD, McCubrey JA, Terrian DM (2007) Cancer Biol Ther 6(8): 1165-70
    › Primary publication · 18059157 (PubMed) · PMC2889025 (PubMed Central)
  28. Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance. McCubrey JA, Steelman LS, Franklin RA, Abrams SL, Chappell WH, Wong EW, Lehmann BD, Terrian DM, Basecke J, Stivala F, Libra M, Evangelisti C, Martelli AM (2007) Adv Enzyme Regul : 64-103
    › Primary publication · 17382374 (PubMed) · PMC2696319 (PubMed Central)
  29. A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells. Lehmann BD, McCubrey JA, Jefferson HS, Paine MS, Chappell WH, Terrian DM (2007) Cell Cycle 6(5): 595-605
    › Primary publication · 17351335 (PubMed)
  30. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA (2007) Biochim Biophys Acta 1773(8): 1263-84
    › Primary publication · 17126425 (PubMed) · PMC2696318 (PubMed Central)